DEVELOPMENT AND VALIDATION OF A NOVEL METHOD FOR CAUSALITY ASSESSMENT USING SUSPECTED ADVERSE DRUG REACTIONS TO ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i11.27749Keywords:
Angiotensin-converting enzyme inhibitors, Adverse drug reaction, Causality, Method, RaterAbstract
Objectives: The study has been designed to develop, test reliability, and construct validity of a novel versatile causality assessment tool (VCAT) method.
Methods: The study included 427 literature case reports of angiotensin-converting enzyme inhibitors with suspected adverse drug reactions from 1990 to February 25, 2016. The causality of these cases was assessed independently by 3 raters in 3 phases of the study. Kappa (k) and intra-class correlation Intraclass Correlation Coefficient (ICC) were used to test reliability and validity of the VCAT method.
Results: Intra-rater reliability was high between Phase I and Phase III (k=0.84–0.93; % agreement: 92.3–96.3%). Inter-rater agreement was good in Phase I (k=0.87–0.89, % agreement: 93.7–94.1%, ICC: 0.975) and Phase III (k=0.85–0.89, % agreement: 93–94.4%, ICC: 0.973). Validity was proved by the high agreement observed between Phase I and Phase II (k=0.78–0.94; % agreement: 89.7–97.2%; p<0.001); and between Phase II and Phase III (k=0.8–0.9; % agreement: 90.2–94.8%; p<0.001).
Conclusion: VCAT method is a standardized causal assessment tool that gives valid and reproducible results. It has shown good agreement with the expert judgment method. This method may overcome the limitations enthralled with existing methods of causality assessment.
Downloads
References
Arimone Y, Miremont-Salame G, Haramburu F, Molimard M, Moore N, Fourrier-Reglat A, et al. Inter-expert agreement of seven criteria incausality assessment of adverse drug reactions. Br J Clin Pharmacol 2007;64:482-8.
Belhekar NM, Taur SR, Munshi RP. A study of agreement between the Naranjo algorithm and WHO-UMC criteria for causality assessment of adverse drug reactions. Indian J Pharmacol 2014;46:117-20.
Mathew E, Chandrika C, Karanath PM, Srinivasa R. A prospective observational study on prescribing trends and adverse drug reactions in stroke patients. Int J Pharm Pharm Sci 2017;9:25-30.
Agbabiaka TB, Savovic J, Ernst E. Methods for causality assessment of adverse drug reactions: A systematic review. Drug Saf 2008;31:21-37.
WHO-Uppsala Monitoring Centre. The use of the WHO-UMC System for Standardised Case Causality Assessment. Available from: http://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf. [Last cited on 2018 Mar 20].
Hire RC, Kinage PJ, Gaikwad NM. Causality assessment in pharmacovigilance: A step towards quality care. Sch J App Med Sci 2013;1:386-92.
Hutchinson TA, Dawid AP, Spiegelhalter DJ, Cowell RG, Roden S. Computerized aids for probabilistic assessment of drug safety I: A spreadsheet program. Ther Innov Regul Sci 1991;25:29-39.
Meyboom RH, Hekster YA, Egberts AC, Gribnau FW, Edwards IR. Causal or casual? The role of causality assessment in pharmacovigilance. Drug Saf 1997;17:374-89.
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
Kane-Gill SL, Forsberg EA, Verrico MM, Handler SM. Comparison of three pharmacovigilance algorithms in the ICU Setting: A retrospective and prospective evaluation of ADRs. Drug Saf 2012;35:645-53.
Parish RC, Miller LJ. Adverse effects of angiotensin converting enzyme (ACE) inhibitors. An update. Drug Saf 1992;7:14-31.
Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
WHO: Global Health Observatory (GHO) Data. Raised Blood Pressure. Available from: http://www.who.int/gho/ncd/risk_factors/blood_pressure_prevalence_text/en/. [Last cited on 2018 Feb 06].
Pere JC, Begaud B, Haramburu F, Albin H. Computerized comparison of six adverse drug reaction assessment procedures. Clin Pharmacol Ther 1986;40:451-61.
Hutchinson TA, Leventhal JM, Kramer MS, Karch FE, Lipman AG, Feinstein AR. An algorithm for the operational assessment of adverse drug reactions. II. Demonstration of reproducibility and validity. JAMA 1979;242:633-8.
Karch FE, Smith CL, Kerzner B, Mazzullo JM, Weintraub M, Lasagna L. Adverse drug reactions: A matter of opinion. Clin Pharmacol Ther 1976;19 5 Pt 1:489-92.
Blanc S, Leuenberger P, Berger JP, Brooke EM, Schelling JL. Judgments of trained observers on adverse drug reactions. Clin Pharmacol Ther 1979;25 5 Pt 1:493-8.
Koch-Weser J, Sellers EM, Zacest R. The ambiguity of adverse drug reactions. Eur J Clin Pharmacol 1977;11:75-8.
Gauravkumar S, Mukeshkumar P, Bhanwarlal J. Safety signal detection of cardiac disorders adverse drug events for azithromycin in pediatric population using health Canada adverse event reporting system database. Int J Pharm Pharm Sci 2017;9:80-4.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
